Zobrazeno 1 - 10
of 264
pro vyhledávání: '"newly diagnosed multiple myeloma"'
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Objective This study aims to identify clinical laboratory parameters for the diagnosis of newly diagnosed multiple myeloma (NDMM), establish optimal cutoffs for early screening, and develop a diagnostic model for precise diagnosis. Methods T
Externí odkaz:
https://doaj.org/article/6793faa069414dac931554fff17d335d
Autor:
Theo Leitner, Evgenii Shumilov, Christina Schwitlick, Raphael Koch, Franziska Hamm, Marion Högner, Florian Bassermann, Katja Weisel, Hermann Einsele, Martin Kortüm, Leo Rasche, Martin Görner, Kai Wegehenkel, Stefan Knop, Jan Krönke, Axel Nogai, Inke R. König, Maren Vens, Kay Horn, Nikolas von Bubnoff, Cyrus Khandanpour
Publikováno v:
Frontiers in Hematology, Vol 3 (2024)
Newly diagnosed multiple myeloma patients who are eligible for transplant usually receive several induction cycles of therapy, followed by one or two cycles of high-dose melphalan and autologous stem cell transfusion. In myeloma patients, high-dose m
Externí odkaz:
https://doaj.org/article/b7669b615e824f3a93d2a84618b32fd6
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Objectives Circular RNA_0003489 (Circ_0003489) promotes multiple myeloma (MM) progression and bortezomib resistance in MM cells, while its potential as a biomarker in newly diagnosed MM (NDMM) patients is unclear. Thus, this study aimed to investigat
Externí odkaz:
https://doaj.org/article/ae636722724849e9bd61d821bf729da8
Autor:
Wee-Joo Chng, Chandramouli Nagarajan, Shang-Yi Huang, Pankaj Malhotra, Yu-Yan Hwang, Vivian Blunk, Manmohan Singh, Lin Wang
Publikováno v:
Heliyon, Vol 10, Iss 21, Pp e39698- (2024)
Multiple myeloma (MM) accounts for almost 15 % of all neoplastic malignancies around the globe. This systematic review intends to analyse data on the treatment and management of MM in selected regions in Asia to identify and prioritize areas that nee
Externí odkaz:
https://doaj.org/article/f234975d478044bc8c3dd95cf441fbb4
Autor:
Terebelo, Howard R. 1, ⁎, Omel, James 2, Wagner, Lynne I. 3, Hardin, James W. 4, Rifkin, Robert M. 5, Ailawadhi, Sikander 6, Durie, Brian G.M. 7, Narang, Mohit 8, Toomey, Kathleen 9, Gasparetto, Cristina J. 10, Joshi, Prashant 11, Yu, Edward 11, Flick, E. Dawn 11, Jou, Ying-Ming 11, Lee, Hans C. 12, Abonour, Rafat 13, Jagannath, Sundar 14
Publikováno v:
In Clinical Lymphoma, Myeloma and Leukemia January 2025 25(1):58-66
Autor:
Costa, Bruno Almeida 1, 2, Costa, Thomaz Alexandre 3, Chagas, Gabriel Cavalcante Lima 4, Mouhieddine, Tarek H. 5, Richter, Joshua 5, Usmani, Saad Z. 1, 6, 7, Mailankody, Sham 1, 7, Rajeeve, Sridevi 1, *, #, Hashmi, Hamza 1, *, ##
Publikováno v:
In Clinical Lymphoma, Myeloma and Leukemia January 2025 25(1):32-44
Autor:
Dong Liang, Xiaojin Li, Shenrui Bai, Qiaoli Wang, Min Zeng, Demei Feng, Bo Lu, Xiaoqing Li, Zhiqiang Sun, Jianyun Li, Huanhuan Zhou, Jialu Zhang, Xiaoqin Chen, Zhongjun Xia, Yang Liang, Hua Wang
Publikováno v:
Cancer Medicine, Vol 13, Iss 20, Pp n/a-n/a (2024)
ABSTRACT Background In the era of novel agents, the clinical outcomes of induction treatment and the impact of the number of high‐risk cytogenetic abnormalities (HRA) in newly diagnosed multiple myeloma (NDMM) need to be explored. Objective Through
Externí odkaz:
https://doaj.org/article/2cad4994be19452ca6b4e2a7f5030cf5
Autor:
Amalia Domingo-González, Rafael Alonso Fernández, Ana Jiménez, Teresa De Soto Álvarez, Ana Lerma-Verdejo, Virginia Pradillo, Gonzalo Benzo Callejo, Jose Sánchez-Pina, Elena Landete, Alberto Velasco-Valdazo, Marina Menéndez-Cuevas, Mónica María López Riñón, Andrés Ramírez-López, María-Jesús Blanchard, Elham Askari
Publikováno v:
Frontiers in Hematology, Vol 3 (2024)
IntroductionThe regimen with daratumumab, bortezomib, melphalan, and prednisone (D-VMP) is one of the recommended treatments for newly diagnosed multiple myeloma (NDMM) non-transplant eligible due to the results described in the ALCYONE trial. Howeve
Externí odkaz:
https://doaj.org/article/1dfd52abead747df8910ff8da4c394eb
Autor:
Chng, Wee-Joo a, b, ⁎, Nagarajan, Chandramouli c, d, Huang, Shang-Yi e, Malhotra, Pankaj f, Hwang, Yu-Yan g, Blunk, Vivian h, Singh, Manmohan i, Wang, Lin i
Publikováno v:
In Heliyon 15 November 2024 10(21)
Publikováno v:
Journal of Inflammation Research, Vol Volume 16, Pp 4117-4121 (2023)
Jing Yuan, Xuan Liu, Zhenzhen Wang, Liyuan Li, Fuxu Wang Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, People’s Republic of ChinaCorrespondence: Fuxu Wang, Department of Hematology, The Seco
Externí odkaz:
https://doaj.org/article/f8bbaeab7fb648cc8e8c808044c1658c